News

Date Title View
Toggle Summary Aerie Pharmaceuticals Announces FDA Advisory Committee Vote in Favor of Rhopressa™ (netarsudil ophthalmic solution) 0.02%
IRVINE, Calif. --(BUSINESS WIRE)--Oct. 13, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other
View HTML
Toggle Summary Aerie Pharmaceuticals Stock Trading Halted Today
FDA Advisory Committee to Review New Drug Application for Rhopressa™ (netarsudil ophthalmic solution) 0.02% IRVINE, Calif. --(BUSINESS WIRE)--Oct. 13, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery,
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of New Members of its Research and Development Team
IRVINE, Calif. --(BUSINESS WIRE)--Oct. 9, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Drug Delivery Asset Acquisition to Further Advance Its Retinal Disease Program
IRVINE, Calif. --(BUSINESS WIRE)--Oct. 5, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Ann Keevans as Director of Human Resources - Europe
IRVINE, Calif. --(BUSINESS WIRE)--Oct. 2, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of New Members of its Commercialization Team
IRVINE, Calif. --(BUSINESS WIRE)--Sep. 29, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Sheila Elliott, PharmD, as Western Regional Director of Medical Science Liaisons
IRVINE, Calif. --(BUSINESS WIRE)--Sep. 25, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML
Toggle Summary Aerie Pharmaceuticals Announces FDA Advisory Committee Meeting for Rhopressa™ (netarsudil ophthalmic solution) 0.02%
Meeting Scheduled for October 13, 2017 IRVINE , Calif.--(BUSINESS WIRE)--Sep. 20, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Tori Arens as Vice President of Drug Product Manufacturing and Eric Carlson, Ph.D. as Vice President of Research and Development
IRVINE, Calif. --(BUSINESS WIRE)--Sep. 19, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of open-angle glaucoma and other diseases of the eye, today
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at Two Investor Conferences in September
IRVINE, Calif. --(BUSINESS WIRE)--Sep. 6, 2017-- Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced
View HTML